Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting HER3 for cancer treatment: a new horizon for an old target

1 Feb 2023

Abstract excerpt

Human epidermal growth factor receptor 3 (HER3) is a member of the human epidermal growth factor receptors family, having as its main ligands neuregulins 1 and 2. Although its poor tyrosine kinase activity entails a weak oncogenic power on its own, HER3 can heterodimerize with HER2 and/or epidermal growth factor receptor (EGFR), leading to a drastic enhancement of transphosphorylation and activation of downstream...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycosylation and Glycoproteins Research
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36764093
DOI: 10.1016/j.esmoop.2023.100790

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting HER3 for cancer treatment: a new horizon for an old targetPMID 36764093Read ↗

HER3/ErbB3, an emerging cancer therapeutic target.Semantic proximity Read ↗

Advances in Targeting HER3 as an Anticancer TherapySemantic proximity Read ↗

Molecular Pathways: HER3 Targeted TherapySemantic proximity Read ↗

HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of CancerSemantic proximity Read ↗

Thirty Years of HER3: From Basic Biology to Therapeutic InterventionsSemantic proximity Read ↗

Understanding the biology of HER3 receptor as a therapeutic target in human cancerSemantic proximity Read ↗

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer TherapySemantic proximity Read ↗

Targeting HER proteins in cancer therapy and the role of the non-target HER3Semantic proximity Read ↗

A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor ResponseSemantic proximity Read ↗

Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination TherapySemantic proximity Read ↗

Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression.Semantic proximity Read ↗

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.